Key Takeaways Intellia completed enrollment in the pivotal phase III HAELO study of lonvo-z for HAE.Top-line HAELO data is expected in early 2026, with a U.S. launch targeted for 1H 2027.First patient in the HAELO study dosed in January 2025, as full enrollment was completed in nine months.Shares of Intellia Therapeutics (NTLA) soared 29.8% yesterday after the company announced that it has completed enrollment in the phase III HAELO study evaluating its investigational candidate, lonvoguran ziclumeran (lonv ...